As mentioned above, DIG-MSK shares with other mithramycin analogues the ability of shifting Sp1 binding, yet its better pharmacological profile [25] suggests that this new mithramycin analogue is a promising drug for the treatment of ovarian cancer. The gene discussed is SP1; the disease is ovarian cancer.